SCHEMBL6073956

SCHEMBL6073956

CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3ncc4cc(Br)c(NC(=O)NC5CCCCC5)nc4n3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 2/20 0.53
CDK4 P11802 2/20 0.53
CCND1 P24385 2/20 0.53
CCND2 P30279 1/20 0.53
CDK2 P24941 2/20 0.49
CCNK O75909 1/20 0.49
CCNA2 P20248 1/20 0.49
CDK9 P50750 1/20 0.49
CDK6 Q00534 1/20 0.49
SYK P43405 8/20 0.49
IGF1R P08069 1/20 0.44
ALK Q9UM73 5/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
EGFR P00533 1/20 0.43
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073878 0.91 CCND3 (0.53) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073923 0.89 CCND3 (0.54) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073780 0.89 CCND3 (0.41) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073783 0.89 CCND3 (0.41) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073426 0.88 CCND3 (0.53) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073880 0.87 CDK4 (0.54) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073855 0.86 CDK4 (0.54) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073499 0.85 CDK4 (0.55) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6074087 0.83 CCND3 (0.62) CCND3CDK4CCND1CCND2CDK2
SCHEMBL6073608 0.82 CDK4 (0.48) CCND3CDK4CCND1CCND2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CCND3 98/4885CDK4 19/4885CCND1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.